Cyclerion Therapeutics Stock Performance
| CYCN Stock | USD 2.75 0.18 6.14% |
On a scale of 0 to 100, Cyclerion Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 2.32, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cyclerion Therapeutics will likely underperform. Please check Cyclerion Therapeutics' standard deviation, expected short fall, relative strength index, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Cyclerion Therapeutics' price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Cyclerion Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Cyclerion Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Year To Date Return (16.29) | Ten Year Return (98.83) | All Time Return (98.83) |
Last Split Factor 1:20 | Last Split Date 2023-05-16 |
1 | Acquisition by Peter Hecht of 15000 shares of Cyclerion Therapeutics subject to Rule 16b-3 | 07/02/2024 |
2 | Disposition of tradable shares by Regina Graul of Cyclerion Therapeutics subject to Rule 16b-3 | 07/03/2024 |
3 | Short Interest in Cyclerion Therapeutics, Inc. Expands By 10.9 percent - Defense World | 07/30/2024 |
4 | Acquisition by Regina Graul of 55849 shares of Cyclerion Therapeutics at 3.3 subject to Rule 16b-3 | 08/05/2024 |
5 | Disposition of 14760 shares by Cheryl Gault of Cyclerion Therapeutics at 16.02 subject to Rule 16b-3 | 09/06/2024 |
| Begin Period Cash Flow | 13.4 M |
Cyclerion |
Cyclerion Therapeutics Relative Risk vs. Return Landscape
If you would invest 272.00 in Cyclerion Therapeutics on June 25, 2024 and sell it today you would earn a total of 21.00 from holding Cyclerion Therapeutics or generate 7.72% return on investment over 90 days. Cyclerion Therapeutics is currently generating 0.6273% in daily expected returns and assumes 11.1276% risk (volatility on return distribution) over the 90 days horizon. In different words, 99% of stocks are less volatile than Cyclerion, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cyclerion Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclerion Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclerion Therapeutics, and traders can use it to determine the average amount a Cyclerion Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0564
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYCN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.13 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Cyclerion Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclerion Therapeutics by adding it to a well-diversified portfolio.
Cyclerion Therapeutics Fundamentals Growth
Cyclerion Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclerion Therapeutics, and Cyclerion Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclerion Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 2.73 M | ||||
| Shares Outstanding | 2.52 M | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 55.50 X | ||||
| Gross Profit | (29.75 M) | ||||
| EBITDA | (9.65 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 30.32 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 2.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 3.49 X | ||||
| Cash Flow From Operations | (21.25 M) | ||||
| Earnings Per Share | (4.29) X | ||||
| Market Capitalization | 7.37 M | ||||
| Total Asset | 13.37 M | ||||
| Retained Earnings | (264.42 M) | ||||
| Working Capital | 5.94 M | ||||
| Current Asset | 109.19 M | ||||
| Current Liabilities | 18.4 M | ||||
About Cyclerion Therapeutics Performance
By examining Cyclerion Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Cyclerion Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cyclerion Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.1 K | 2.1 K | |
| Return On Tangible Assets | (1.57) | (1.65) | |
| Return On Capital Employed | (0.85) | (0.81) | |
| Return On Assets | (1.57) | (1.65) | |
| Return On Equity | (1.86) | (1.77) |
Things to note about Cyclerion Therapeutics performance evaluation
Checking the ongoing alerts about Cyclerion Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclerion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclerion Therapeutics is way too risky over 90 days horizon | |
| Cyclerion Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclerion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
| Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
| Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 14760 shares by Cheryl Gault of Cyclerion Therapeutics at 16.02 subject to Rule 16b-3 |
- Analyzing Cyclerion Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclerion Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cyclerion Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclerion Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclerion Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclerion Therapeutics' stock. These opinions can provide insight into Cyclerion Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.